Company intelligence / Profile preview

XenoPort, Inc.

Santa Clara, California, United Statesbusinesswire.com ↗

Ownership: Private
Employees: ~114
Development stage: NDA

Overview

XenoPort had commercialized Horizant (gabapentin enacarbil) for restless legs syndrome and postherpetic neuralgia in the US, and Regnite in Japan through Astellas Pharma. The company was acquired by Arbor Pharmaceuticals in 2016 for approximately $467 million.

Therapeutic areas: DermatologyPsychiatryNeurology
Modalities: Small moleculesprodrugs
Industry: Biotech

Drug pipeline

1 asset

Solzira

NDA

Indications: Moderate-to-severe primary restless legs syndrome

Partnerships

Astellas Pharma (for Regnite in Japan)Dr. Reddy's Laboratories (for XP23829 in psoriasis)Indivior (for arbaclofen placarbil)National Institute on Alcohol Abuse and Alcoholism (for Horizant in alcohol use disorder)

Beyond the preview

Go deeper on XenoPort, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XenoPort, Inc..

Explore the full profile